(Reporting by Puyaan Singh; Editing by Shilpi Majumdar)
AstraZeneca to cap US out-of-pocket costs for inhalers to $35
(Reuters) - AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products for chronic lung disease and asthma to $35 per month, starting June, in the United States.